- Home
- PETS vs MRNS Comparison
PETS vs MRNS Comparison
Compare PETS & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- MRNS
- Stock Information
- Founded
- PETS 1996
- MRNS 2003
- Country
- PETS United States
- MRNS United States
- Employees
- PETS N/A
- MRNS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- MRNS Health Care
- Exchange
- PETS Nasdaq
- MRNS Nasdaq
- Market Cap
- PETS 82.0M
- MRNS 104.7M
- IPO Year
- PETS N/A
- MRNS 2014
- Fundamental
- Price
- PETS $4.07
- MRNS $0.31
- Analyst Decision
- PETS Sell
- MRNS Buy
- Analyst Count
- PETS 2
- MRNS 12
- Target Price
- PETS $3.50
- MRNS $4.56
- AVG Volume (30 Days)
- PETS 182.6K
- MRNS 5.7M
- Earning Date
- PETS 11-06-2024
- MRNS 11-05-2024
- Dividend Yield
- PETS 29.41%
- MRNS N/A
- EPS Growth
- PETS N/A
- MRNS N/A
- EPS
- PETS N/A
- MRNS N/A
- Revenue
- PETS $270,772,000.00
- MRNS $30,263,000.00
- Revenue This Year
- PETS N/A
- MRNS $21.18
- Revenue Next Year
- PETS $3.27
- MRNS $56.42
- P/E Ratio
- PETS N/A
- MRNS N/A
- Revenue Growth
- PETS 2.26
- MRNS 16.56
- 52 Week Low
- PETS $2.90
- MRNS $0.26
- 52 Week High
- PETS $8.27
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- PETS 56.76
- MRNS 21.75
- Support Level
- PETS $3.78
- MRNS $0.29
- Resistance Level
- PETS $4.17
- MRNS $1.96
- Average True Range (ATR)
- PETS 0.18
- MRNS 0.12
- MACD
- PETS -0.01
- MRNS -0.18
- Stochastic Oscillator
- PETS 62.22
- MRNS 2.41
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.